Olema Pharmaceuticals Appoints New CFO Jason O’Byrne

What Happened

• Olema Pharmaceuticals (OLMA) filed a Form 8-K reporting the appointment of Jason O’Byrne as Chief Financial Officer, principal financial officer and principal accounting officer. The Board approved the appointment on July 28, 2026; the appointment is effective August 11, 2026 and was announced by press release on August 13, 2026.
• Mr. O’Byrne joins from Vir Biotechnology (served Oct 2024–Aug 2026) and previously held senior finance roles at Caribou Biosciences, Audentes Therapeutics and Genentech/Roche. The company filed the Offer Letter (Exhibit 10.1) and the press release (Exhibit 99.1) with the 8-K.

Key Details

• Base salary: $545,000 per year; target annual bonus: 45% of base salary.
• Sign-on bonus: $250,000 payable within 30 days of the effective date and $100,000 payable within 30 days after the first anniversary (both subject to certain repayment obligations).
• Equity: inducement option to purchase 650,000 shares under the 2022 Inducement Plan, vesting over four years (25% at one year, then monthly thereafter).
• Severance/benefits: if terminated without Cause or resigns for Good Reason within a specified Change‑in‑Control window, eligible for 12 months’ salary + target bonus, prorated bonus, accelerated vesting, and up to 12 months COBRA; similar 12‑month protections apply outside the CIC window with partial accelerated vesting conditions.

Why It Matters

• This is a material executive change affecting Olema’s financial leadership. Investors should note the compensation and equity package (including a sizable option grant) which can affect future dilution and expense. The severance and CIC provisions are typical retention protections but can be relevant in scenarios involving leadership transitions or corporate transactions. The filing confirms there are no related‑party issues disclosed and that the company delayed public disclosure until its press announcement.